Expand Document | Expand Chapter | Full TOC | Printable HTML version
First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Sources of information and study methodology
Open this folder and view contents3. Dissemination and uptake of the Guidelines
Open this folder and view contents4. Basic characteristics of drug donations
Open this folder and view contents5. Practical benefits as a result of the Guidelines
View the document6. Drug donations which were hampered, delayed or cancelled
Open this folder and view contents7. Experiences and opinions regarding the 12-month shelf-life requirement
Open this folder and view contents8. Other suggestions to improve the Guidelines
Open this folder and view contents9. How could donation practice be further improved?
View the document10. Summary of recommendations
View the document11. Postscript
View the documentReferences
 

10. Summary of recommendations

The chapters of this report contain a number of recommendations made by those who replied to the questionnaires. They are reproduced below and are followed in the postscript by a brief account of the subsequent outcome and action taken.

• WHO and all partner organizations should continue to actively disseminate the Interagency Guidelines for Drug Donations, and should encourage all governments and organizations involved in drug donations to formulate their own guidelines.

• A special education effort should be made with regard to all recipient governments, informing them about the Guidelines, with emphasis on the guideline for the minimum shelf-life of donations upon arrival, the exceptions provided for, and the need for rapid customs clearance of donated drugs.

• A special education effort should be made with regard to all donors and consolidators, in order to reduce the number and quantities of short-dated drugs offered for donation.

• WHO should establish a system whereby recipients and consolidators can report examples of inappropriate donations or unacceptable donation practices.

• WHO should convene the interagency group and propose to it an update of the Guidelines, including the incorporation of the current text of the exception for direct donations into the main body of the text of Article 6, in order to prevent that guideline from being copied and used without proper consideration of the exception.

• WHO should expand the section on the management of drug donations in the next version of the Guidelines, stressing the need for rapid clearance of drug donations and reconfirming the justification of certain exceptions to the minimum shelf-life provision.

• WHO should involve as many partners as possible in the next version of the Guidelines. International organizations which have expressed an interest should be invited to become co-sponsors of the second version. Examples of such organizations are Caritas Internationalis, the United Nations Population Fund and the World Bank.

to previous section to next section
 

Last updated: May 3, 2013